New depression drug shows promise in early trial
NCT ID NCT06842992
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new medicine, NH102, to see if it helps with major depression. 243 adults with depression took part. The goal was to check if NH102 reduces symptoms like sad mood and sleep problems better than a placebo or an existing drug. The results will help design larger future studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Mental Health Center
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can couples counseling lift depression in women?
- Brain wave clues: could inflammation markers forecast ECT outcomes?
- Can tailored brain zaps beat standard therapy for depression?
- Can a new daily pill lift the fog of depression?
- Can a new pill outsmart depression? a trial puts KH607 to the test
- Depression's biological fingerprint: a quest for objective diagnosis and personalized treatment